Gilead finds CAR-T manufacturing costly but says Kite’s is ‘superb’ and cost-efficient – FiercePharma
FiercePharma |
Gilead finds CAR–T manufacturing costly but says Kite’s is ‘superb’ and cost-efficient
FiercePharma Gilead Sciences is betting nearly $12 billion on Kite Pharma’s CAR–T technology, and one of the factors that influenced it is Kite’s readiness to handle the complex and time-sensitive manufacturing and logistics demanded by the personalized cell … Bio Roundup: CAR–T’s Huge Week, Merck’s ‘Pib Choice & MoreXconomy Gilead’s Acquisition Of Kite Pharma Relieves Shareholders’ EnnuiSeeking Alpha |
WeAreGreenBay.com |
Healthwatch: Gene Therapy
WeAreGreenBay.com GREEN BAY, Wis. (WFRV) – (CBS News) The Food and Drug Administration approved a treatment that engineers a patient’s own blood cells to fight cancer. It’s the first type of gene therapy to hit the U-S market. It has already been used to treat children … |
The Institute of Cancer Research (blog) |
America approves ‘revolutionary’ CAR T cell immunotherapy — what does this mean for cancer patients?
The Institute of Cancer Research (blog) The treatment, known as CAR T cell therapy, was shown to be effective against blood cancers in clinical trials, and has just been approved by the Food and Drug Administration in the US specifically for children and young adults who have acute … Cancer treatment breakthrough just the beginning for new therapiesThe New Daily |
KSDK |
FDA approves breakthrough gene therapy for childhood leukemia
KSDK The Food and Drug Administration said the approval on Wednesday was historic, the first gene therapy to hit the U.S. market. Made from scratch for every patient, it’s one of a wave of “living drugs” under development to fight additional blood cancers … Pioneering gene therapy approved for leukaemia in the USNew Scientist FDA approval brings first gene therapy to the United StatesFDA.gov First Gene Therapy Treatment Approved in USSmithsonian Los Angeles Times –Novartis –National Cancer Institute –National Cancer Institute all 597 news articles » |
|
Oxford BioMedica could get $100 following CAR–T approval
pharmaphorum UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ chimeric antigen receptor T–cell (CAR-T) therapy … |